A clinical study was conducted to compare effectiveness of IV Globulin with that of steriod in childhood acute ITP. We carried out an experiment to 36 patients of acute ITP who recovered over 50.000/mm(3) of platelet count and not to recur in 6 months. Study group consist of 10 children who were treated with steriod only (Group A), 13 children who were treated with IV Globulin (0.4g/kg/d, 5 days, Group B), and 13 children combined with steroid (Group C) Study period was from January 1988 to December 1992, folllowing results were obtained. 1) There were no significant difference in sex ratio. age distribution, pretreatment hemoglobin level, platelet count and prolonged bleeding time among study groups. 2) The days which platelet count reached to 50.000/mm(3), 100,000/mm(3) were 3.7 days (Group A), 2.1 days (Group B), and 2.3 days (Group C), respectively (p<0.05). 3) Complete response rates within 4 weeks did not show significant difference (90% in Group A, 84.6% in Group B, 92.3% in Group C), the complete response rate within 1 week were significantly different among three group (44.4% in Group A, 90.9% in Group B, 83.3% in Group C)(p<0.05). In conclusion, it is more desirable for early treatment of a childhood ITP because IV Globulin is easy to normalize platelet count in a short time.
Age Distribution ; Bleeding Time ; Child ; Humans ; Platelet Count ; Sex Ratio

The effects of hemocoagulase in injectable form(hemocoagulating enzymatic fraction of South American snake Botrops Jararaca venom provided by Ravizza) on the control of intraocular bleeding during vitreous surgery were evaluated in rabbit eyes. Intraocular infusion solution with hemocoagulase(1 NIH thrombin unit/100 ml BSS) significantly reduced the bleeding time to 33.2 +/- 9.7 seconds. Electroretinogram b-wave and electroretinogram c-wave showed no abnormality. Infusate with hemocoagulase appeared to be a favorite agent for the control of intraocular bleeding during viteous surgery.
Batroxobin* ; Bleeding Time ; Bothrops ; Hemorrhage* ; Snakes ; Thrombin ; Venoms

Factor Vll deficiency has an estimated incidence of 1/500,000 in the general population and autosomal recessive pattern of inheritance. Factor Vll deficiency is characterized by prolonged prothrombin time (PT), and normal activated partial thromboplastin time (aPTT) and bleeding time (BT). Definite diagnosis of this condition requires a specific Factor Vll assay. The clinical features are variable and do not always correlate with the Factor Vll level. We experienced a case of Factor Vll deficiency presenting as hemarthroses in a 2-years-old girl, whose chief complaint was pain, swelling of right knee joint and limping gait. The laboratory findings were prolonged PT and prominent deficiency of factor Vll. So, we report a case of Factor Vll deficiency with a brief review of the related literature.
Bleeding Time ; Diagnosis ; Female ; Gait ; Hemarthrosis* ; Humans ; Incidence ; Knee Joint ; Partial Thromboplastin Time ; Prothrombin Time ; Wills

Factor Vll deficiency has an estimated incidence of 1/500,000 in the general population and autosomal recessive pattern of inheritance. Factor Vll deficiency is characterized by prolonged prothrombin time (PT), and normal activated partial thromboplastin time (aPTT) and bleeding time (BT). Definite diagnosis of this condition requires a specific Factor Vll assay. The clinical features are variable and do not always correlate with the Factor Vll level. We experienced a case of Factor Vll deficiency presenting as hemarthroses in a 2-years-old girl, whose chief complaint was pain, swelling of right knee joint and limping gait. The laboratory findings were prolonged PT and prominent deficiency of factor Vll. So, we report a case of Factor Vll deficiency with a brief review of the related literature.
Bleeding Time ; Diagnosis ; Female ; Gait ; Hemarthrosis* ; Humans ; Incidence ; Knee Joint ; Partial Thromboplastin Time ; Prothrombin Time ; Wills

OBJECTIVE: This review aimed to present the experience of the Micro-surgery Unit of the Department of Orthopedics of the UP-PGH, in the use of fasciocutaneous rotation-advancement flap coverage for sacral decubitus ulcers.

METHODS: A review of patient referred to the unit of management of sacral decubitus ulcers, from 2003-2009. All patients with grades III or IV ulcers, managed with fasciocutaneous flap coverage, and with a minimum follow-up of 1 month were included in the study. Demographic data for all patients were retrieved including albumin level at the time of surgery, operative time, blood loss, complication and status of flap.

RESULTS: Twenty-five patients were included in the analysis. The mean age of the patients was 57 years (with a range of 18-78 years). The average operative time was 2.7 hours±1.1 hours and the average blood loss was 428 ml (range, 100 - 500 ml). With a mean follow-up of 9.6 months, there were 3 recurrences and 2 mortalities. Twelve complications were documented in the 25 patients. Seventy-two percent (18/25) had healed sacral flaps on final follow-up.

Human ; Pressure Ulcer ; Ulcer ; Orthopedics ; Operative Time ; Surgical Flaps ; Bleeding Time ; Sacrum ; Orthopedic Procedures ; Recurrence ; Albumins

Dextran is a macromolecular polymer of dextrose. Dextran is used as a plasma expander with reduction in blood viscosity and disruption of red cell aggregates. It also inhibits platelet aggregation and prothrombin activation. It has been reported that a hemostatic defect characterized by a prolonged bleeding time in subject receiving large amount of dextran. The present study was undertaken to observe the effect of dextran on bleeding time and platelet aggregation by increasing volume. In this study, bleeding time was checked and sampling was done at before infusion, after 5 ml/kg, 10 ml/kg and 15 ml/kg infusion of dextran in 15 patients with spinal or regional anesthesia. The results were as follows: 1) There was prolonged bleeding time by increasing volume of dextran 40, but within nonnal limit. 2) There was no platelet aggregation with 15ml/kg of dextran.
Anesthesia, Conduction ; Bleeding Time ; Blood Platelets* ; Blood Viscosity ; Dextrans* ; Glucose ; Humans ; Plasma ; Platelet Aggregation ; Polymers ; Prothrombin

30 patients were randomly divided into three groups : halothane in oxygen(N=10) ; enflurane in oxygen(N= 10) ; Thalamonal plus nitrous oxide in oxygen(N= 10). Standardized bleeding time was measured using Ivy method before and at leaat 40 min after the induction of anesthesia. Arterial pressure was maintained at+/- 200 of control values and tem-perature was kept at 35~37 degrees C. The bleeding time was prolonged by 58% in the halothane group (P<0.001). There was essentially no change in bleeding time in the groups receiving enflurane and nitrous oxide-Thalamonal group, although there was considerable variability within each group, which did not seem to be related to differences in sex, age, type of surgery, concentration of agent used or surgical procedure. In conclusion, our resultg suggest that halothane may be contraindicated in situations where optimal hemostasis is critical.
Anesthesia ; Arterial Pressure ; Bleeding Time* ; Enflurane* ; Halothane* ; Hemorrhage* ; Hemostasis ; Humans ; Nitrous Oxide

The postoperative analgesic effects of firocoxib in ovariohysterectomized cats were observed. Twenty-four cats were divided into 3 groups: control (no medicine), firocoxib-1 (1 mg/kg/day) and firocoxib-3 (3 mg/kg/day). Colorado pain scale scores (CPSS), composite pain scores (CPS), and buccal mucosal bleeding times (BMBT) were recorded in blinded fashion before induction and 2, 5, 8, 24, 30, and 48 h post-operation. The average CPSS (mean ± SEM) over 2 to 48 h post-operation in firocoxib-3 (0.4 ± 0.1) was significantly lower than that of the control (0.7 ± 0.2; p = 0.004), but that of firocoxib-1 (0.5 ± 0.2) was not different from that of the control (p = 0.40). The mean CPS of firocoxib-3 was significantly lower than that of the control at 24 h post-operation (p = 0.04); nonetheless, there was no significant difference in mean CPS between firocoxib-1 and control groups at all intervals. BMBT and body temperature were within normal limits in all groups. However, reversible azotemia was identified in two firocoxib-3 cats at 72 h post-operation. One firocoxib-3 cat vomited once at 48 h post-operation. In conclusion, firocoxib-3 is helpful for postoperative pain control in cats; however, gastrointestinal irritation and renal function side effects may occur.
Analgesia ; Animals ; Azotemia ; Bleeding Time ; Body Temperature ; Cats* ; Colorado ; Pain, Postoperative ; Prostaglandin-Endoperoxide Synthases

Fourty-eight mongrel dogs were bled to half the level of their control aystolic blood pressures and infused with Hartmanns solution, low molecular weight dextran, whole blood, or with Hartmann's solution+low molecular weight dextran (1:1 or 1:3) in the amount equivalent to the blood loss. Bleeding time, coagulation time, platelet count and erythrocyte sedimentation rate were examined 6 hours and 24 hours after the completion of infusion. The results are as follows: 1) No changes in blood coagulability other than due to hemodilution were observed in dogs infused with Hartmann's solution, whole blood, or 1:1 Hartmann's solution+low molecular weight dextran. 2) Significant changes in blood coagulability were noted, however, in dogs infused with low molecular weight dextran alone or 1:3 Hartmann's solution+low molseular weight dextran. These changes seem to be related rather to decreased platelet function than to the decease in platelet number.
Animals ; Bleeding Time ; Blood Platelets ; Blood Sedimentation ; Dextrans ; Dogs ; Fluid Therapy* ; Hemodilution ; Molecular Weight ; Platelet Count

There are still some controversies regarding one stage repair of pectus deformity with congenital heart disease due to probable complications after extensive resection of deformed cartilages. We performed Nuss operation with simultaneous intracardiac repair in 8 year old patient with pectus excavatum and partial atrioventricular septal defect. The result of operation was satisfactory without prolongation of operation time, bleeding or instability of chest wall.
Bleeding Time ; Cartilage ; Child ; Congenital Abnormalities ; Funnel Chest ; Heart Defects, Congenital ; Humans ; Thoracic Wall ; Thorax